The U.S. FDA has granted IND clearance for SGT-212, intended for treating Friedreich's Ataxia, with first participant dosing anticipated in the second half of 2025.
Friday, May 16, 2025
Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates
GuruFocus News. 16/05/2025
